Semaglutide Weight Loss Results: What to Expect Week by Week

By NuvaMed Medical Team · May 2026 · 8 min read

The most common question we get: "How much weight will I actually lose, and how fast?" Here's what the clinical data says — and what to realistically expect at each stage.

What the Clinical Trials Show

The STEP (Semaglutide Treatment Effect in People with Obesity) trials enrolled over 4,500 adults across multiple studies. The headline results:

Weeks 1–4: The Adjustment Phase

Starting dose: 0.25mg weekly

The first month is about letting your body adjust. Your physician prescribes a low starting dose intentionally — not because it produces significant weight loss, but because it dramatically reduces side effects while your GI system adapts.

What most patients experience:

• Reduced appetite, particularly for high-calorie foods
• Feeling full faster during meals
• Possible mild nausea (especially the first 1–2 days after injection)
• Modest weight loss: 2–5 lbs in the first month is typical

The "food noise" reduction — the constant background thoughts about eating — is often the first thing patients notice, and many describe it as the most meaningful change.

Months 2–3: The Active Loss Phase

Dose titrated to 0.5mg, then 1.0mg

This is when most patients see noticeable, visible changes. As the dose increases, appetite suppression becomes more pronounced and weight loss accelerates.

• Average cumulative loss by month 3: 5–10% of starting body weight
• Nausea typically subsides for most patients
• Clothes fit differently; people around you may comment
• Energy levels often improve as metabolic health improves

Months 4–6: Sustained Progress

Dose at 1.7mg or 2.4mg (maintenance dose)

• Most patients in clinical trials lost 10–13% of starting weight by month 6
• Weight loss rate slows somewhat compared to months 2–3 — this is normal
• Many patients see improvements in blood pressure, blood sugar, and cholesterol
• Physical activity becomes easier and more natural

Months 6–12: Maximum Efficacy

Clinical trials show that weight loss typically plateaus around months 9–12 at the maximum tolerated dose:

• Average trial participant: 15–17% total body weight lost
• Top third of responders: 20–25% or more
• Bottom third of responders: 8–12% (still clinically meaningful)

Factors That Affect Your Results